投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名 称及人员姓 名 招商基金、西部利得基金、永赢基金、中信保诚基金、东兴基金、 平安资管、泰康资管、浙商证券资管、北京羲和金泰资管、华宝信 托、兴银理财、汇华理财、电科投资、淡水泉(北京)投资、广东正 圆私募基金、深圳市一诺私募基金、和基投资基金、益民基金、华 夏财富创新投资、上海臻宜投资、上海睿亿投资、深圳市红石榴投 资、博观私募、橡果资产、循远投资、茂典资产、新余善思投资、 上海天猊投资、中信建投、国盛证券、海通证券、国金证券、东吴 证券、东方证券、东北证券、东兴证券、华福证券、中邮证券、大 和证券、华宝证券等约 40 余家机构和个人。 时间 2025 年 01 月 24 日 地点 电话会议 上市公司接 待人员姓名 董事、总裁：肖益 董事、财务总监、董事会秘书：满孝国 副总裁：谷桐宇 副总裁：梁敏燕 证券投资部总经理：蒋帆 | | 总体情况介绍 | | --- | --- | | | 2024 年，是易华录并入中国电科体系的第一个完整年度，公司 | | | 内部也开展了一系列 ...

证券代码：301596 证券简称：瑞迪智驱 成都瑞迪智驱科技股份有限公司 投资者关系活动记录表 编号：2025-002 投资者关系活动 类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 人员姓名 一、2025 年 1 月 22 日 国泰君安、汇添富基金共计 8 人 二、2025 年 1 月 24 日 浙商证券、信达证券、泰康保险资管共计 8 人 时间 2025 年 1 月 22 日-1 月 24 日 地点 成都市双流区西航港大道中四段 909 号 上市公司接待人 员姓名 董事、董事会秘书、副总经理：刘兰 投资者关系活动 主要内容介绍 一、公司介绍 由公司董事、董事会秘书、副总经理刘兰女士介绍主营业务情况、产品介 绍等。 二、互动交流 1、请问公司产品的技术来源及传承？ 回复：通过多年的技术沉淀和经验积累，公司拥有为多行业进行高效定制 化设计的技术优势。公司深刻理解客户需求，并结合公司自主研发的机械精密 加工技术、电磁制动器定制化设计技术、产品开发测试及应用验证技术、制动 器摩擦材料配方与制造工艺以及长寿命重载型 ...

证券代码：002127 证券简称：南极电商 南极电商股份有限公司投资者关系活动记录表 编号：2025-004 | 投资者关系活 | √ 特定对象调研 □ 分析师会议 | | | | --- | --- | --- | --- | | 动类别 | □ 媒体采访 □ 业绩说明会 | | | | | 路演活动 □ 新闻发布会 | | □ | | | □ 现场参观 | | | | | □ 其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 华泰国际、国海证券、长安基金、招银理财、东海基金、信 | | | | 及人员姓名 | 诚基金、建信基金 | | | | 时间 | 2025 年 1 月 23 日-24 日 | | | | 地点 | 公司会议室 | | | | 上市公司接待 | 董事会秘书：朱星毓 | | | | 人员姓名 | | | | | | 一、介绍公司基本情况 | | | | | 公司 2024 年度业绩预告已发布，2024 年公司业务收入预 | | | | | 计实现 32 亿元-35 亿元，同比获得较大幅度增长，得益于公 | | | | | 司品牌升级及业务结构调整，南极人品牌在 2024 ...

Group 1: Strategic Goals - The company aims to achieve a total sales volume of 5 million vehicles by 2030, with 3.5 million being new energy vehicles and 30% of sales coming from overseas markets [1] - The strategic layout includes the "13335" plan, which encompasses 1 innovation plan, 3 sub-plans (new energy, intelligence, globalization), 3 major brands (Changan, Deep Blue, Avita), and 5 overseas markets [1] Group 2: Overseas Market Plans - In 2025, the company plans to launch the Rayong factory in Southeast Asia, marking the entry into the 2.0 phase of its globalization strategy [2] - The company will hold a brand launch event in Europe and establish a subsidiary in Brazil for the South American market [2] - The company will implement KD projects in the CIS region, including Kazakhstan and Uzbekistan [2] Group 3: New Energy Initiatives - Over the next 5 years, the company plans to introduce 50 new smart products, including six large SUVs and MPVs [3] - The goal is to create over 5 models with a production target of 300,000 units each, driving high-quality development across the supply chain [3] - The company aims to achieve mass production of the next-generation battery by 2030 [3] Group 4: Digitalization and Technology - The company is focused on advancing its smart chassis and distributed electric drive technologies, aiming to become an industry leader in high-level intelligent driving by 2027 [4] - Future plans include the development of flying cars and humanoid robots, contributing to a new multi-dimensional transportation ecosystem [4] Group 5: Market Insights - The global automotive market is projected to approach 100 million units by 2025 and exceed 108 million units by 2030 [5] - China's automotive sales are expected to surpass 32 million units in 2025 and exceed 35 million units by 2030 [6] - The penetration rate of new energy vehicles is expected to increase, with a projected ratio of EV, XEV, and ICE vehicles reaching 4:4:2 in the next 3-5 years [6]

证券代码：301009 证券简称：可靠股份 杭州可靠护理用品股份有限公司投资者关系活动记录表 编号：2025-001 投资者关系活 动类别 □特定对象调研 □分析师会议 媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 （电话会议、线上会议） 参与单位名称 及人员姓名 2025 年 1 月 24 日 10:00-11:00：天风证券：孙海洋、张彤；泰康资产： 蒋雪莹、王琦、蒋友松；阳光资管：吴彬；上海混沌投资：黎晓楠；财 通资管：赵雯；泰康基金：刘书琴；工银：何睿豪；银河基金：杨琪；中 国国际金融：袁咪；上海五聚资管：王鑫；前海云溪基金：李志勇；循 远资管：田超平；广东正圆投资：亓辰；上海泾溪投资：柯伟；德懿禾 资管：赵哲锐；上海原泽私募基金：姚珊；创金合信基金：梁雪；上海 煜德投资：程跃；北京诚盛投资：完永东 2025 年 1 月 24 日 11:00-12:00：西南证券：蔡欣、沈琪 时间 2025年1月24日 10:00-11:00；11:00-12:00 地点 电话会议、线上会议 上市公司参与 人员姓名 副总经理兼财务总监：李超楠 资本运营总监：王向亭 证券投资经理兼证券事务代表：周 ...

Group 1: Financial Performance and Projections - In 2024, the company expects to achieve revenue of approximately 900 million to 920 million CNY, representing a growth of about 8% to 11% [2] - The net profit for 2024 is projected to be between 180 million to 200 million CNY, with an impact on net profit attributable to shareholders of approximately 90 million to 100 million CNY [2] - The pharmaceutical and medical services segment is anticipated to generate revenue of around 400 million to 420 million CNY, with a growth rate of approximately 25% to 30% [2] Group 2: Strategic Investments and Costs - The company has increased its capital investment and expenses to seize strategic opportunities in the MASH industry, leading to a rise in total expenses by approximately 9 million to 10 million CNY [4][6] - Key investments include hiring a Chief Medical Officer and expanding the sales team, particularly in North America and Europe [5] - The company has incurred additional costs of 6.23 million EUR in salaries, 1.8 million EUR in training, and 1.39 million EUR in depreciation due to these investments [6] Group 3: Market Challenges and Adjustments - Delays in clinical results for Novo Nordisk's semaglutide MASH indication have pushed back the deployment of related equipment [7] - The market demand for new drugs targeting existing MASH patients has been lower than expected, affecting sales strategies [8] - The company has opted for a cautious approach in increasing equipment deployment, focusing on training and monitoring existing devices [9] Group 4: 2025 Strategic Goals - The company aims to install 4,000 devices and sell 1,600 devices in 2025, with a focus on high-end hospitals in developed markets [11] - The target for the GO and BOX series devices is set at 2,400 units, representing a significant increase from 2024 [11] - The company plans to enhance its market penetration for core devices like FibroScan, particularly among high-risk liver cancer populations [10] Group 5: Collaboration and Confidence - The partnership with Novo Nordisk includes market access coordination, sales expansion, and clinical trial support [11] - The company expresses strong confidence in achieving its 2025 installation target due to favorable industry trends and comprehensive preparations [11] - Over 5,200 peer-reviewed publications and more than 200 national and international guidelines support the company's strategic direction [11]

Sales Performance - The pharmaceutical segment achieved a revenue of 4.069 billion CNY in H1 2024, a year-on-year growth of 9.6% [2] - Sales of Yunnan Baiyao aerosol exceeded 1.2 billion CNY, with a growth rate of over 30% [2] - The sales revenue of the herbal medicine product "Pudilan" surpassed 100 million CNY, with nearly double-digit growth [2] - The "Gongxue Ning" capsule saw a 36% increase in sales revenue year-on-year [2] - The "Qixue Kang" oral liquid achieved sales exceeding 100 million CNY, while "Sanjia Renfeng" oral liquid grew over 80% year-on-year [2] Marketing and Growth Strategies - The company implemented various growth strategies focusing on clinical research, marketing, channel development, and production efficiency [3][4] - A basketball event in collaboration with universities attracted 512 teams and generated over 290 million views on Douyin [4] - The online channel expansion resulted in approximately 350 million exposures and 2.96 million interactions, driving over 1.052 million visitors to e-commerce platforms [4] - The GMV for e-commerce grew by 47% year-on-year [4] Health Products Performance - Yunnan Baiyao toothpaste maintained its leading market share in the domestic oral care sector [5] - The "Yangyuanqing" hair care products generated 195 million CNY in sales, with a growth rate of 41% [5] - The brand achieved top rankings in the Tmall and Douyin platforms during the "618" shopping festival [5][6] Traditional Chinese Medicine Resources - The Chinese medicine resources segment reported an operating revenue of 894 million CNY in H1 2024, a year-on-year increase of approximately 22% [7] - The average order delivery rate was 99.36%, stabilizing raw material prices significantly below industry averages [7] - The natural plant extraction business saw a revenue growth of 47% [7] Channel Development - The marketing network covers over 40,000 retail pharmacies and 5,000 major chain stores nationwide [9] - The company collaborates with major e-commerce platforms like Alibaba, JD, and Douyin to enhance online sales channels [9] - Continuous optimization of both traditional and emerging sales channels has strengthened market competitiveness [9]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey and on-site visit [2] - Participants included representatives from various investment firms and individual investors [2] - The meeting took place on January 23, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - The meeting involved discussions on relevant questions regarding the company's performance [2] Group 3: Attendees - Notable attendees included representatives from Pacific Securities, Ningbo Zhiyuan, and other investment firms [2] - Company representatives included securities affairs representative and investor relations management personnel [2]

富奥汽车零部件股份有限公司 投资者关系活动记录表 3、问：公司新能源客户拓展情况如何？ 答：在新能源领域，公司以客户商务评级制度为基础， 着重聚焦优质新能源客户，在比亚迪、蔚来汽车、小鹏汽车、 宁德时代、零跑汽车等新能源企业均获取了优质订单。 4、问：电控减振器的客户有哪些？ 答：电控减振器产品主要客户为金康赛力斯、奇瑞、吉 利、红旗、零跑等。 编号：2025-03 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他 | | 活动参与人员 | 华创证券 | | 时间 | 2025 年 1 月 24 日 14:30-15:30 | | 地点 | 富奥汽车零部件股份有限公司 | | 形式 | 座谈 | | 上市公司接待人 | 董事会秘书：李延军 | | | 研发中心副主任：李伟 | | 员姓名 | 预算分析主管：张嘉琳 | | | 综合事务主管：沈相君 | | | 1、问：公司在新能源汽车零部件市场的布局进展如何？ | | | 答：公司按照"轻量化、电动化、智 ...

编号：2025-001 投资者关系活动类别 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及人员姓名 中信证券 杜一帆 朱伟康 何锦鹏 平安养老 邹译萱 时间 2025 年 1 月 24 日 10:00 至 11:30 地点 公司会议室 上市公司接待人员姓名 庞维聆、谢云晴、陆裔宸 投资者关系活动主要内容 介绍 1、问：公司 2024 年第四季度和 2025 年第一季度经 营情况如何？ 答：公司积极把握传统销售旺季与促消费政策落地 显效等有利契机，2024 年第四季度销售环比第三季 度有明显提升。截止目前，2025 年第一季度销售同 比上升，主要受春节较同期提前影响。 2、问：各门店空置率情况如何？ 答：公司旗下主要百货门店经营模式以联营为主， 辅以租赁业态，空置率较低。公司将以满铺经营为 目标，做好品牌引进以及供应商储备工作，持续关 注新兴业态，为公司业态转型升级打下基础。 3、问：公司奥特莱斯当前运营状况如何？ 答：2024 年，汇金奥莱受车站整体改造及线上电商 分流等因素影响，客流以及业绩呈现下滑趋势。随 证券代码：002561 证券简 ...